Friday , July 3 2020
Home / BUSINESS / EQUITIES / Abraxis Biosciences LLC withdraws complaint against SPARC’s Taclantis injection
Download Udaipur Kiran App to read Latest News Today

Abraxis Biosciences LLC withdraws complaint against SPARC’s Taclantis injection

Sun Pharma Advanced Research Company’s (SPARC) patent infringement complaint regarding its New Drug Application for Taclantis injection PICS (Paclitaxel Injection Concentrate for Suspension) has been withdrawn by Abraxis Bioscience LLC. The company will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.

Earlier, Abraxis Biosciences LLC has filed a complaint against the company in the US District Court for the district of New Jersey. It alleged that the SPARC’s filing of New Drug Application (NDA) for Taclantis injection (Paclitaxel Injection Concentrate for Suspension) is an act of infringement of the Orange Book listed patents for Abraxane.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Please share this news